The company manufactures and prints flexible plastic packaging materials, such as films and pouches, primarily serving industrial clients in the food, personal care, and pharmaceutical sectors.
The company operates in a highly fragmented and commoditized industry with no evidence of pricing power, as reflected in the razor-thin net margins of 1.8% and low ROCE of 9.2%. While management claims innovation and R&D breakthroughs, the financials show a business that struggles to earn its cost of capital.
Capital has been deployed toward expanding capacity and working capital, yet EPS has declined by 35.8% despite revenue growth. Frequent issuance of convertible warrants to non-promoters suggests a reliance on external funding rather than internal cash generation to sustain operations.
The business collapsed under the weight of its own capital structure as the interest coverage ratio of 1.0 left zero margin for error. While revenue grew, the inability to convert sales into cash—evidenced by negative cash conversion and ballooning receivables—forced a reliance on dilutive warrant issuances to stay liquid. Eventually, the mismatch between razor-thin margins and rising debt costs led to a liquidity crunch, where the company could no longer service its obligations or fund the working capital required to maintain its commoditized operations.
RichFakir rates Sabar Flex India Ltd's business quality as poor — 18/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Sabar Flex India Ltd is trading about 10% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Sabar Flex India Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Sabar Flex India Ltd's fair value is about ₹10 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →